Pacific Standard Distributors, Inc. – Trademark Portfolio
Entity Type: 03
Pacific Standard Distributors, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 29 (Meats & Processed Foods) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MODIFILAN. The owner is based in Sandy, OR.
34480 SE Colorado Road
Sandy, OR 97055
Showing of trademarks Trademarks
Trademark Classifications
Pacific Standard Distributors, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits
Frequently Asked Questions
How many trademarks does Pacific Standard Distributors, Inc. have?
Pacific Standard Distributors, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 3 cancelled.
What trademark classes does Pacific Standard Distributors, Inc. file in?
Pacific Standard Distributors, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 29 (Meats & Processed Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Pacific Standard Distributors, Inc.'s most well-known trademarks?
Pacific Standard Distributors, Inc.'s registered trademark portfolio includes well-known marks such as MODIFILAN. These are among 1 currently registered trademark in the portfolio.
What is Pacific Standard Distributors, Inc.'s trademark registration success rate?
Pacific Standard Distributors, Inc. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.